Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 160Myelodysplastic Syndromes 44Leukemia, Myelomonocytic, Chronic 25Leukemia 16Myeloproliferative Disorders 11Recurrence 9Hematologic Neoplasms 8Neoplasms 6Lymphoma, T-Cell, Peripheral 6Primary Myelofibrosis 5Leukemia, Biphenotypic, Acute 5Anemia, Refractory, with Excess of Blasts 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Leukemia, Monocytic, Acute 4Hematologic Diseases 4GATA2 Deficiency 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Polycythemia Vera 2Lymphoma, T-Cell 2

Interventions

Rituximab 85Cyclophosphamide 80Prednisone 47Doxorubicin 43Lenalidomide 36Vincristine 34Magnetic Resonance Spectroscopy 29polatuzumab vedotin 28Gemcitabine 26Etoposide 26Specimen Handling 25fludarabine 23Biopsy 21Oxaliplatin 20CT-P10 20glofitamab 16tafasitamab 15obinutuzumab 15ibrutinib 13fludarabine phosphate 13zanubrutinib 12axicabtagene ciloleucel 12Immunotherapy, Adoptive 12Ifosfamide 12venetoclax 11pembrolizumab 11deltacortene 11prednylidene 10Prednisolone 10Leukapheresis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Azacitidine × 1 year × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡